USA - engelsk - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 500 mg - clarithromycin extended-release tablets are indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae, haemophilus parainfluenzae, moraxella catarrhalis, or streptococcus pneumoniae [see indications and usage ( 1.9)] . clarithromycin extended-release tablets (in adults) are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae, moraxella catarrhalis, or streptococcus pneumoniae [see indications and usage ( 1.9)] . clarithromycin extended-release tablets are indicated [see indications and usage ( 1.9)] for the treatment of mild to moderate infections caused by susceptible isolates due to: - haemophilus influenzae (in adults) - haemophilus parainfluenzae (in adults) - moraxella catarrhalis (in adult

USA - engelsk - NLM (National Library of Medicine)

lannett company, inc. - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 250 mg - clarithromycin tablets, usp are indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae , haemophilus parainfluenzae , moraxella catarrhalis , or streptococcus pneumoniae [see indications and usage (1.9)] . clarithromycin tablets, usp are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae , moraxella catarrhalis , or streptococcus pneumoniae [see indications and usage (1.9)] . clarithromycin tablets, usp are indicated [see indications and usage (1.9)] for the treatment of mild to moderate infections caused by susceptible isolates due to: - haemophilus influenzae (in adults) - mycoplasma pneumoniae , streptococcus pneumoniae , chlamydophila pneumoniae clarithromycin tablets, usp are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to streptococ

USA - engelsk - NLM (National Library of Medicine)

sandoz inc - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 125 mg in 5 ml - clarithromycin is indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae , haemophilus parainfluenzae , moraxella catarrhalis , or streptococcus pneumoniae [see indications and usage (1.9) ]. clarithromycin is indicated for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae , moraxella catarrhalis , or streptococcus pneumoniae [see indications and usage (1.9) ]. clarithromycin is indicated [see indications and usage (1.9) ] for the treatment of mild to moderate infections caused by susceptible isolates due to: clarithromycin is indicated for the treatment of mild to moderate infections caused by susceptible isolates due to streptococcus pyogenes as an alternative in individuals who cannot use first line therapy. clarithromycin is indicated for the treatment of mild to moderate infections caused by susceptible isolates due to staphylococcus aureus , or streptococcus pyogenes . cl

USA - engelsk - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 500 mg - clarithromycin tablets, usp are indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae , haemophilus parainfluenzae , moraxella catarrhalis , or streptococcus pneumoniae [see indications and usage (1.9)] . clarithromycin tablets, usp are indicated for the treatment of mild to moderate infections c

USA - engelsk - NLM (National Library of Medicine)

mayne pharma inc. - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 500 mg - clarithromycin extended-release tablets are indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae, haemophilus parainfluenzae, moraxella catarrhalis, or streptococcus pneumoniae [see indications and usage (1.9)] . clarithromycin extended-release tablets (in adults) are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae, moraxella catarrhalis, or streptococcus pneumoniae [see indications and usage (1.9)] . clarithromycin extended-release tablets are indicated [see indications and usage (1.9)] for the treatment of mild to moderate infections caused by susceptible isolates due to: - haemophilus influenzae (in adults) - haemophilus parainfluenzae (in adults) - moraxella catarrhalis (in adults) - mycoplasma pneumoniae, streptococcus pneumoniae , chlamydophila pneumoniae (in adults) clarithromycin extended-release tablets are indicated only for acute maxillary s

USA - engelsk - NLM (National Library of Medicine)

wockhardt usa llc. - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 250 mg - clarithromycin tablets, usp are indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae , haemophilus parainfluenzae , moraxella catarrhalis , or streptococcus pneumoniae [see indications and usage (1.9)] . clarithromycin tablets, usp (in adults) are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae , moraxella catarrhalis , or streptococcus pneumoniae [see indications and usage (1.9)] . clarithromycin tablets, usp are indicated [see indications and usage (1.9)] for the treatment of mild to moderate infections caused by susceptible isolates due to: - haemophilus influenzae (in adults) - haemophilus parainfluenzae (in adults) - moraxella catarrhalis (in adults) - mycoplasma pneumoniae , streptococcus pneumoniae , chlamydophila pneumoniae (in adults and pediatric patients) clarithromycin tablets, usp are indicated for the treatment of mild to mo

USA - engelsk - NLM (National Library of Medicine)

ranbaxy pharmaceuticals inc. - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - tablet, film coated, extended release - 1000 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of clarithromycin extended-release tablets and other antibacterial drugs, clarithromycin extended-release tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. the efficacy and safety of clarithromycin extended-release tablets in treating other infections for which other formulations of clarithromycin are approved have not been established. clarithromycin is contraindicated in patients with a known hypersensitivity to clarithromycin, erythromycin, or any of the macrolide antibiotics. concomitant administration of clarithromycin and any of the following drugs is contraindicated: cisapride, p

USA - engelsk - NLM (National Library of Medicine)

remedyrepack inc. - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 500 mg - clarithromycin tablets, usp are indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae , haemophilus parainfluenzae , moraxella catarrhalis , or streptococcus pneumoniae [see indications and usage (1.9)] . clarithromycin tablets, usp are indicated for the treatment of mild to moderate infections c

USA - engelsk - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 500 mg - clarithromycin extended-release tablets are indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae, haemophilus parainfluenzae, moraxella catarrhalis, or streptococcus pneumoniae [see indications and usage ( 1.9)] . clarithromycin extended-release tablets (in adults) are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae, moraxella catarrhalis, or streptococcus pneumoniae [see indications and usage ( 1.9)] . clarithromycin extended-release tablets are indicated [see indications and usage ( 1.9)] for the treatment of mild to moderate infections caused by susceptible isolates due to: - haemophilus influenzae (in adults) - haemophilus parainfluenzae (in adults) - moraxella catarrhalis (in adult

USA - engelsk - NLM (National Library of Medicine)

aurobindo pharma limited - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 250 mg - clarithromycin tablets are indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae , haemophilus parainfluenzae , moraxella catarrhalis , or streptococcus pneumoniae [see indications and usage (1.9)]. clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae , moraxella catarrhalis , or streptococcus pneumoniae [see indications and usage (1.9)]. clarithromycin tablets are indicated [see indications and usage (1.9)]  for the treatment of mild to moderate infections caused by susceptible isolates due to: - haemophilus influenzae (in adults) - mycoplasma pneumoniae , streptococcus pneumoniae , chlamydophila pneumoniae (clarithromycin tablets [in adults and pediatric patients]) clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to streptococcus pyogenes as an alternative in indiv